Penumbra Pre-Tax Profit Margin 2014-2022 | PEN

Current and historical pre-tax profit margin for Penumbra (PEN) from 2014 to 2022. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue. Penumbra pre-tax profit margin for the three months ending June 30, 2022 was .
Penumbra Pre-Tax Profit Margin Historical Data
Date TTM Revenue TTM Pre-Tax Income Pre-Tax Margin
2022-06-30 $0.81B $-0.04B -4.84%
2022-03-31 $0.78B $-0.03B -3.58%
2021-12-31 $0.75B $-0.01B -1.47%
2021-09-30 $0.71B $0.03B 4.08%
2021-06-30 $0.67B $0.00B 0.15%
2021-03-31 $0.59B $-0.03B -4.39%
2020-12-31 $0.56B $-0.04B -6.96%
2020-09-30 $0.54B $-0.03B -4.83%
2020-06-30 $0.53B $0.01B 1.33%
2020-03-31 $0.56B $0.04B 6.83%
2019-12-31 $0.55B $0.05B 9.32%
2019-09-30 $0.52B $0.05B 8.80%
2019-06-30 $0.50B $0.01B 2.63%
2019-03-31 $0.47B $0.01B 1.91%
2018-12-31 $0.45B $0.00B 0.45%
2018-09-30 $0.42B $-0.00B -0.24%
2018-06-30 $0.39B $0.02B 5.09%
2018-03-31 $0.36B $0.01B 2.47%
2017-12-31 $0.33B $0.00B 0.60%
2017-09-30 $0.31B $-0.00B -1.29%
2017-06-30 $0.29B $-0.01B -2.04%
2017-03-31 $0.28B $-0.01B -1.80%
2016-12-31 $0.26B $-0.00B -0.38%
2016-09-30 $0.24B $0.00B 1.23%
2016-06-30 $0.23B $0.01B 2.64%
2016-03-31 $0.20B $0.00B 0.98%
2015-12-31 $0.19B $0.00B 2.16%
2015-06-30 $0.11B 0 0.00%
Sector Industry Market Cap Revenue
Medical Medical Instruments Manufacturing $6.042B $0.748B
Penumbra, Inc. is an interventional therapies company. It designs, develops, manufactures and markets medical devices. The company's portfolio of products primarily addresses neuro and peripheral vascular medical conditions and clinical needs. Neuro products include Neurovascular Access, Neuron Access System, BENCHMARK Intracranial Access System, Penumbra System, 3D, Penumbra Coil 400, Penumbra SMART Coil and LIBERTY stent. Peripheral vascular products include Ruby Coil System, Penumbra Occlusion Device and Indigo System. It operates primarily in U.S., Europe, Canada and Australia. Penumbra, Inc. is headquartered in Alameda, California.
Stock Name Country Market Cap PE Ratio
Thermo Fisher Scientific (TMO) United States $227.578B 23.18
Edwards Lifesciences (EW) United States $62.887B 44.49
Alcon (ALC) Switzerland $36.987B 31.32
STERIS (STE) Ireland $20.913B 25.96
Teleflex (TFX) United States $11.693B 18.63
Fresenius Medical Care AG KGaA (FMS) Germany $10.936B 10.09
Globus Medical (GMED) United States $6.491B 32.38
Glaukos (GKOS) United States $2.370B 0.00
Integer Holdings (ITGR) United States $2.345B 18.34
Nevro (NVRO) United States $1.688B 0.00
Paragon 28 (FNA) United States $1.486B 0.00
AVANOS MEDICAL, INC (AVNS) United States $1.365B 20.90
Artivion (AORT) United States $0.860B 82.00